Cutaneous Reactions in Children Treated with the Mitogen-Activated Protein Kinase Extracellular Signal-Regulated Kinase Inhibitor Trametinib for Neural Tumors

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Background: The mitogen-activated protein kinase (MAPK) pathway is a target for the treatment of a growing number of malignancies. The cutaneous reactions to medications that inhibit this pathway have not been described in children. Methods: A retrospective chart review was completed for eight children with neural tumors treated with the MAPK extracellular signal-regulated kinase inhibitor trametinib. All children were evaluated by a pediatric dermatologist with documentation of cutaneous findings. Results: All patients had at least two separate skin reactions while on treatment with trametinib. Common skin findings included xerotic dermatitis, bacterial folliculitis, acneiform eruptions, paronychia, and hair thinning. No child needed to discontinue use of trametinib due to cutaneous toxicities. Conclusions: Cutaneous reactions are common in children receiving trametinib. Identification of these reactions is the initial step in establishing treatment guidelines that will minimize skin eruptions and subsequent interruption of trametinib treatment.

Original languageEnglish (US)
Pages (from-to)90-94
Number of pages5
JournalPediatric Dermatology
Volume34
Issue number1
DOIs
StatePublished - Jan 1 2017

Fingerprint

Extracellular Signal-Regulated MAP Kinases
Mitogen-Activated Protein Kinases
Skin
Neoplasms
Acneiform Eruptions
Paronychia
Folliculitis
Dermatitis
Therapeutics
trametinib
Documentation
Hair
Guidelines
Pediatrics

PubMed: MeSH publication types

  • Journal Article

Cite this

@article{ea1b28b2aa964bdcbb2a1bcd76a9adcf,
title = "Cutaneous Reactions in Children Treated with the Mitogen-Activated Protein Kinase Extracellular Signal-Regulated Kinase Inhibitor Trametinib for Neural Tumors",
abstract = "Background: The mitogen-activated protein kinase (MAPK) pathway is a target for the treatment of a growing number of malignancies. The cutaneous reactions to medications that inhibit this pathway have not been described in children. Methods: A retrospective chart review was completed for eight children with neural tumors treated with the MAPK extracellular signal-regulated kinase inhibitor trametinib. All children were evaluated by a pediatric dermatologist with documentation of cutaneous findings. Results: All patients had at least two separate skin reactions while on treatment with trametinib. Common skin findings included xerotic dermatitis, bacterial folliculitis, acneiform eruptions, paronychia, and hair thinning. No child needed to discontinue use of trametinib due to cutaneous toxicities. Conclusions: Cutaneous reactions are common in children receiving trametinib. Identification of these reactions is the initial step in establishing treatment guidelines that will minimize skin eruptions and subsequent interruption of trametinib treatment.",
author = "Boull, {Christina L} and Hook, {Kristen P} and Moertel, {Christopher L} and Sheilagh Maguiness",
year = "2017",
month = "1",
day = "1",
doi = "10.1111/pde.13038",
language = "English (US)",
volume = "34",
pages = "90--94",
journal = "Pediatric Dermatology",
issn = "0736-8046",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Cutaneous Reactions in Children Treated with the Mitogen-Activated Protein Kinase Extracellular Signal-Regulated Kinase Inhibitor Trametinib for Neural Tumors

AU - Boull, Christina L

AU - Hook, Kristen P

AU - Moertel, Christopher L

AU - Maguiness, Sheilagh

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Background: The mitogen-activated protein kinase (MAPK) pathway is a target for the treatment of a growing number of malignancies. The cutaneous reactions to medications that inhibit this pathway have not been described in children. Methods: A retrospective chart review was completed for eight children with neural tumors treated with the MAPK extracellular signal-regulated kinase inhibitor trametinib. All children were evaluated by a pediatric dermatologist with documentation of cutaneous findings. Results: All patients had at least two separate skin reactions while on treatment with trametinib. Common skin findings included xerotic dermatitis, bacterial folliculitis, acneiform eruptions, paronychia, and hair thinning. No child needed to discontinue use of trametinib due to cutaneous toxicities. Conclusions: Cutaneous reactions are common in children receiving trametinib. Identification of these reactions is the initial step in establishing treatment guidelines that will minimize skin eruptions and subsequent interruption of trametinib treatment.

AB - Background: The mitogen-activated protein kinase (MAPK) pathway is a target for the treatment of a growing number of malignancies. The cutaneous reactions to medications that inhibit this pathway have not been described in children. Methods: A retrospective chart review was completed for eight children with neural tumors treated with the MAPK extracellular signal-regulated kinase inhibitor trametinib. All children were evaluated by a pediatric dermatologist with documentation of cutaneous findings. Results: All patients had at least two separate skin reactions while on treatment with trametinib. Common skin findings included xerotic dermatitis, bacterial folliculitis, acneiform eruptions, paronychia, and hair thinning. No child needed to discontinue use of trametinib due to cutaneous toxicities. Conclusions: Cutaneous reactions are common in children receiving trametinib. Identification of these reactions is the initial step in establishing treatment guidelines that will minimize skin eruptions and subsequent interruption of trametinib treatment.

UR - http://www.scopus.com/inward/record.url?scp=85006918701&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85006918701&partnerID=8YFLogxK

U2 - 10.1111/pde.13038

DO - 10.1111/pde.13038

M3 - Article

VL - 34

SP - 90

EP - 94

JO - Pediatric Dermatology

JF - Pediatric Dermatology

SN - 0736-8046

IS - 1

ER -